BiotechTube
Home/Pipeline/New targets program

New targets program

ALS

PreclinicalActive

Key Facts

Indication
ALS
Phase
Preclinical
Status
Active
Company
Treeway

About Treeway

Treeway is a patient-founded, Netherlands-based biotech focused on the formidable challenge of treating neurodegenerative diseases like ALS and Alzheimer's. Its lead asset, TW001, is an oral formulation of edaravone being developed for Alzheimer's disease, with Phase 2 results recently accepted for a late-breaking presentation. The company operates with a lean, expert team and leverages strategic academic and industry collaborations to advance its preclinical and clinical pipeline.

View full company profile

Therapeutic Areas

Amyotrophic Lateral Sclerosis (ALS)Alzheimer's DiseaseNeurodegenerative Diseases

Other ALS Drugs

DrugCompanyPhase
Stem Cell ProgramBioArcticResearch
Eolo40 NCEEolo PharmaDiscovery
SYF2 ProgramAcuraStemDiscovery
Target-03Verge GenomicsDiscovery
Target-04Verge GenomicsDiscovery
BIIB105 (ATXN2 ASO)BiogenPhase 2
Undisclosed Programbioarctic-abDiscovery